A TRISPECIFIC ROR1 X CD3 T CELL ENGAGER MEDIATES IN VITRO TUMOR CELL KILLING AND IN VIVO TUMOR ERADICATION

被引：1

作者：

Chatterjee, Bithi ^{[1
]}

Snell, Daniel ^{[1
]}

Hess, Christian ^{[1
]}

Brock, Matthias ^{[1
]}

Spiga, Fabio ^{[1
]}

Simonin, Alexandre ^{[1
]}

Gunde, Tea ^{[1
]}

Warmuth, Stefan ^{[1
]}

Weinert, Christopher ^{[1
]}

Bassler, Nicole ^{[1
]}

Kirk, Niels ^{[1
]}

Schumacher, Nina ^{[1
]}

Mahler, Dana ^{[1
]}

Yaman, Yasemin ^{[1
]}

Bommer, Bettina ^{[1
]}

Gambino, Giorgio ^{[1
]}

Giezendanner, Noreen ^{[1
]}

Kuettner, Benjamin ^{[1
]}

Flueckiger, Naomi ^{[1
]}

Heiz, Robin ^{[1
]}

Wagen, Sandro ^{[1
]}

Diem, Dania ^{[1
]}

Zeberer, Julia ^{[1
]}

Urech, David ^{[1
]}

机构：

[1] Numab Therapeut, Wadenswil, Switzerland

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.844

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

844

引用

页码：A885 / A885

页数：1

共 50 条

[21] LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8+ T Cells
Kim, Aeryon
Han, Chia-Jung
Driver, Ian
Olow, Aleksandra
Sewell, Andrew K.
Zhang, Zemin
Ouyang, Wenjun
Egen, Jackson G.
Yu, Xin
JOURNAL OF IMMUNOLOGY, 2019, 203 (04): : 1076 - 1087
[22] A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model
Meckler, Joshua F.
Levis, Daniel J.
Vang, Daniel P.
Tuscano, Joseph M.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (09) : 2939 - 2948
[23] ESTABLISHING THE PRECLINICAL PKPD RELATIONSHIP FOR NM32-2668 A ROR1 TARGETING T CELL ENGAGER
Mistry, Hitesh
Ortega, Fernando
Chatterjee, Bithi
Bassler, Nicole
Kirk, Niels
Tietz, Julia
Wickihalder, Belinda
Muntwiler, Simone
Carnal, Simon
Snell, Daniel
Chassagnole, Christophe
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1343 - A1343
[24] Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia
Gohil, Satyen H.
Evans, Rachel
Harasser, Micaela
El-Kholy, Mohamed
Paredes-Moscosso, Solange R.
Della Peruta, Marco
Nathwani, Amit C.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (02) : 380 - 382
[25] Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo
Zhong, Liping
Shi, Wei
Gan, Lu
Liu, Xiuli
Huo, Yu
Wu, Pan
Zhang, Zhikun
Wu, Tao
Peng, Hongmei
Huang, Yong
Zhao, Yongxiang
Yuan, Yulin
Deng, Zhiming
Tang, Hongliang
THERANOSTICS, 2021, 11 (13): : 6393 - 6406
[26] Erratum: A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
S Hipp
Y-T Tai
D Blanset
P Deegen
J Wahl
O Thomas
B Rattel
P J Adam
K C Anderson
M Friedrich
Leukemia, 2017, 31 : 2278 - 2278
[27] Development of a humanized ROR1 x CD3 bispecific DART molecule for the treatment of solid and liquid tumors
Barat, Bhaswati
Chichili, Gurunadh
Ciccarone, Valentina
Tamura, James
Gorlatov, Sergey
Spliedt, Michael
Chen, Francine
Koenig, Scott
Moore, Paul
Bonvini, Ezio
Alderson, Ralph
Johnson, Syd
CANCER RESEARCH, 2016, 76
[28] A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement
Chen, Li
Qian, Wenjing
Pan, Fangfang
Li, Debin
Yu, Weiwei
Tong, Li
Yang, Yingying
Xu, Qiming
Ding, Jianfeng
Dai, Ruixue
Xian, Weiwei
Zhu, Xufeng
Ren, Pu
Zhu, Huaxing
IMMUNOTHERAPY, 2024, 16 (03) : 143 - 159
[29] Role of CD4+CD25+ regulatory T cells in allospecific tumor cell killing in vitro
Drago, KF
Hoffman, P
Negrin, JER
Edinger, M
FASEB JOURNAL, 2003, 17 (07): : C78 - C78
[30] ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth
Zhang, Suping
Chen, Liguang
Cui, Bing
Chuang, Han-Yu
Yu, Jianqiang
Wang-Rodriguez, Jessica
Tang, Li
Chen, George
Basak, Grzegorz W.
Kipps, Thomas J.
CANCER RESEARCH, 2012, 72

← 1 2 3 4 5 →